Tsai, C., Ko, H., Chiou, S., Lai, Y., Hou, C., Javaria, T., . . . Hong, Y. (2021). NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. Int J Mol Sci.
Stile di citazione ChicagoTsai, Cheng-Yu, et al. "NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme By Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating P53-Mediated MGMT Inhibition." Int J Mol Sci 2021.
Citazione MLATsai, Cheng-Yu, et al. "NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme By Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating P53-Mediated MGMT Inhibition." Int J Mol Sci 2021.